FDA open to use of new MRD endpoint ahead of advisory committee meeting
The FDA seems open to a new endpoint that could accelerate the development of new treatments for multiple myeloma.
The agency’s Oncologic Drugs Advisory Committee …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
